A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

Type 2 Diabetes Mellitus Clinical Trial

Official title:

A Phase II, Open-Label Safety and Tolerability Study of an Renal Autologous Cell Therapy (REACT) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03270956
• Other study ID #: REGEN-003
• Status: Completed
• Phase: Phase 2
• Start date: April 25, 2018
• Est. completion date: November 17, 2022

Study information

• Verified date: January 2023
• Source: Prokidney
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).

Description:

All subjects enrolled will receive REACT. Subjects will receive their first REACT injection as soon as the REACT product is manufactured and shipped to the clinical site. After 6 months (+4 weeks), a second injection will be given, as appropriate. Each subject's baseline rate of renal decline, based on adequate historical clinical data obtained 24 months prior to screening visit, will serve as a comparator for monitoring the rate of progression of renal insufficiency over time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: November 17, 2022
• Est. primary completion date: November 17, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. The subject is male or female, 30 to 65 years of age on the date of informed consent.

2. The subject has an established diagnosis of T2DM.

3. The subject has an established diagnosis of diabetic nephropathy as the underlying cause of renal disease.

4. The subject has an established diagnosis of CKD not requiring renal dialysis, defined as having an eGFR between 14 and 20 mL/min/1.73m² inclusive at the Screening Visit and prior to REACT injection.

5. The subject has blood pressure less than 150/90 at the Screening Visit, prior to renal biopsy, and prior to REACT injection(s). Note BP should not be significantly below the previously recorded stable pressure.

6. A minimum of 3 measurements of eGFR or sCr should be obtained at least 3 months apart prior to the Screening Visit or within the previous 24 months to define the rate of progression of CKD. The subject should have adequate, historical clinical data to provide a reasonable estimate of the rate of progression of CKD. The Medical Monitor may be consulted to ensure there is sufficient data.

Exclusion Criteria:

1. The subject has a history of type 1 diabetes mellitus.

2. The subject has a history of renal transplantation.

3. The subject has a serum HbA1c level greater than 10% at the Screening Visit.

4. The subject has uncontrolled diabetes (defined as metabolically unstable by the Investigator).

5. The subject has hemoglobin levels less than 9 g/dL prior to each REACT injection.

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Diabetes Mellitus, Type 2
• Kidney Diseases
• Renal Insufficiency, Chronic
• Type 2 Diabetes Mellitus

Intervention

Biological:
• Renal Autologous Cell Therapy (REACT)
Autologous selected renal cells (SRC)

Locations

Country	Name	City	State
United States	Boise Kidney & Hypertension Institute	Boise	Idaho
United States	University of North Carolina- Chapel Hill	Chapel Hill	North Carolina
United States	Vanderbilt University [WITHDRAWN]	Nashville	Tennessee
United States	University of Arizona [WITHDRAWN]	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Prokidney	CTI Clinical Trial and Consulting Services

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Procedure and/or product related adverse events	Incidence (percentage of subjects) with procedure and/or product related adverse events by System Order Class and Preferred Term	Through 24 months following last REACT injection
Secondary	Renal specific adverse events	Incidence (percentage of subjects) with renal-specific adverse events by System Order Class and Preferred Term	Through 24 months following last REACT injection